Tetra Bio-Pharma Initiates Additional Studies On Leading Drug Candidate ARDS-003

• Tetra Bio-Pharma and Targeted Pharmaceuticals enter into an agreement to further its collaboration and co-development activities to advance Antiviral Central Nervous System Program
• The addressable global market for central nervous system drugs is expected to grow to $163.05B in 2025

Tetra Bio-Pharma Inc. ("Tetra" or the "Company"), a biopharmaceutical pioneer in immunomodulator drug discovery and development announce they have initiated other research projects with Targeted Pharmaceuticals through its research agreement with the George Mason University NCBID to investigate the potential benefits of ARDS-003 in neuroinflammation and other antiviral applications.

The global central nervous system drugs market is expected to grow from $125.28B in 2020 to $163.05B in 2025 at a CAGR of 6%. (ref: Feb 2021, The Business research company).

Dr. Guy Chamberland, CEO and CRO commented, "We have initiated this new research agreement to further understand the potential therapeutic benefits of ARDS-003 in treating inflammatory conditions of the brain as well as learning more about the potential use of the drug candidate in other antiviral applications. The partnership with Targeted provides expertise into these areas of drug development that are critical for expanding the potential Return on Investment of our lead drug candidate ARDS-003."